Anasetti C et al.
Are matched unrelated donor transplants justified for AML in CR1?
Best Pract Res Clin Haematol 2006;19:321-328.
Aversa F et al.
Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.
J Clin Oncol 2005;23:3447-3454.
Ball ED et al.
Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up.
Bone Marrow Transplant 2000;25:823-829.
Bensinger WI et al.
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.
N Engl J Med 2001;344:175-181.
Buchner T et al.
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
J Clin Oncol 2006;24:2480-2489.
Burnett AK et al.
Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties.
Cassileth PA et al.
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
N Engl J Med 1998;339:1649-1656.
Chalandon Y et al.
Influence of cytogenetic abnormalities on outcome after allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission.
Biol Blood Marrow Transplant 2002;8:435-443.
Collisson EA et al.
Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission.
Craddock C et al.
Biology and management of relapsed acute myeloid leukaemia.
Br J Haematol 2005;129:18-34.
de Botton S et al.
Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group.
J Clin Oncol 2005;23:120-126.
de Lima M et al.
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.
The role of allogeneic transplantation in high-risk acute myelogenous leukemia.
Eyrich M et al.
A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigen-disparate haematopoietic stem cells from parental donors.
Br J Haematol 2001;114:422-432.
Farag SS et al.
Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
J Clin Oncol 2005;23:482-493.
Giralt S et al.
Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Marrow purging: present status and future perspectives - efficacy in AML.
Prog Clin Biol Res 1992;377:251-262.
Gorin NC et al.
Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Co-operative Group for Bone Marrow Transplantation (EBMT).
Hegenbart U et al.
Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.
J Clin Oncol 2006;24:444-453.
Heldal D et al.
Donation of stem cells from blood or bone marrow: results of a randomised study of safety and complaints.
Bone Marrow Transplant 2002;29:479-486.
Jourdan E et al.
One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.
Br J Haematol 2005;129:403-410.
Kolb HJ et al.
Tolerance and chimerism.
Kolb HJ et al.
Graft-versus-leukemia reactions in allogeneic chimeras.
Kroger N et al.
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Bone Marrow Transplant 2000;26:711-716.
Lang P et al.
A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients: preliminary results of a pilot study.
Klin Pädiatr 2005;217:334-338.
Lashkari A et al.
Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of patients > or =60 years with acute myelogenous leukemia.
Biol Blood Marrow Transplant 2006;12:466-471.
Li L et al.
Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens.
Cancer Immunol Immunother 2005;54:685-693.
Miller JS et al.
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.
Park KD et al.
In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive Cord Blood lymphocytes.
Platzbecker U et al.
Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia.
Rocha V et al.
Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.
N Engl J Med 2004;351:2276-2285.
Scheffold C et al.
Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+ donor cell chimerism analysis.
Schmid C et al.
Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation.
Slavin S et al.
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Socie G et al.
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
Stelljes M et al.
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Storb R et al.
Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation.
Suciu S et al.
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.
Thiede C et al.
Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers.
Thiede C et al.
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.
Wong R et al.
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
Biol Blood Marrow Transplant 2005;11:108-114.
Yanada M et al.
Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis.